Optimizing Oocyte Quality in Polycystic Ovary Syndrome (PCOS): The Impact of Neurotrophin-4 in In Vitro Maturation Protocols

A 28-year-old female with polycystic ovary syndrome (PCOS) and a history of primary infertility for eight years underwent <i>in vitro</i> maturation (IVM) at Wardha. The patient's clinical profile revealed elevated levels of anti-Müllerian hormone (AMH) levels, a high luteinizing hormone/follicle-stimulating hormone (LH/FSH) ratio, and ultrasound findings consistent with PCOS. After mild ovarian stimulation, 12 immature oocytes were retrieved and cultured in Neurotrophin-4 (NT-4) enriched IVM medium. A total of eight oocytes matured to the metaphase II stage, with seven achieving fertilization via intracytoplasmic sperm injection (ICSI). Out of the fertilized oocytes, five developed into high-quality blastocysts. The patient received an optimized endometrial preparation protocol, including metformin, estradiol, cabergoline, and L-arginine supplementation. Following frozen embryo transfer, pregnancy was confirmed by positive beta-human chorionic gonadotropin (<i>β</i>-hCG) levels and ultrasound. This study highlights IVM's potential to mitigate ovarian hyperstimulation syndrome (OHSS) risks while achieving high success rates in PCOS patients. The inclusion of NT-4 in maturation media significantly improved oocyte quality, fertilization rates, and blastocyst development. These findings underscore IVM as a promising assisted reproductive technology (ART) approach, offering enhanced safety and efficacy for fertility treatment in PCOS patients.